CanadaHizentra immunoglobulin solution (200 mg/mL), Market Authorization DIN 02498251, lot P100834475 sold nationally in Canada is affected; verify the product using the DIN and lot number. The recall was issued because the appearance is out of specification. Verify if your product is affected, consult your healthcare provider before stopping use, contact CSL Behring Canada with questions, and report side effects or other safety complaints to Health Canada.
What's being recalled
Depth of recall: End Users
Companies: CSL Behring Canada, Inc., 55 Metcalfe Street, Suite 350, Ottawa, ON, K1P 6L5.
How to identify it
Product Name: Hizentra; Market Authorization: DIN 02498251; Dosage Form: Solution; Strength: IMMUNOGLOBULIN (HUMAN) 200 mg/mL; Lot numbers: P100834475
The hazard
The appearance is out of specification in the affected lot.
What to do
Verify if your product is affected.
Consult your healthcare provider prior to discontinuing use of the affected product(s), or for any health concerns.
Contact the recalling firm if you have any questions about the recall.
Report any health product related side effects to Health Canada.
Report any other health product safety complaints to Health Canada.
Where it was sold
National
The official notice
This page is a summary of the notice published by Health Canada, collected from Health Canada, CFIA and Transport Canada. Check the original before you act on it.
Read the official notice (opens in a new tab)